Clinical trial for soft tissue sarcoma drug on track

The drug could deliver higher doses of doxorubicin without the same levels of toxicity.

CytRx Corporation has announced that it plans to conduct a phase 2b clinical trial of its potential soft tissue sarcoma drug aldoxorubicin are on track thanks to success in the patient enrolment process.

Those involved have been able to recruit 105 evaluable patients, and the cohort size will enable them to fairly evaluate the efficacy of the drug against the currently-used doxorubicin in a head-to-head study.

Although this approved medicine is effective in targeting a variety of cancers, the severity of side-effects restricts the dosage that can be administered and as such compromises patient outcomes.

Aldoxorubicin has been developed in such a way that it should deliver doxorubicin directly to diseased regions, thus allowing doctors to utilise higher strengths while limiting the potential for side-effects.

In the clinical trial, patients with metastatic locally advanced or unresectable soft tissue sarcoma who have not previously undergone chemotherapy will be randomly assigned doxorubicin or aldoxorubicin that delivers 3.5-times the dose.

Evidence that it offers similar or superior anti-cancer effects without toxicity will warrant further research and the pursuit of approval for the pharmaceutical market.